In mid-morning trading on Monday, the Dow Jones industrials were up 0.04% while the S&P 500 was down 0.07% and the Nasdaq 0.22% lower.
Before markets opened on Monday, M&T Bank posted better-than-expected profits thanks to higher interest rates. Net interest income doubled to $1.83 billion year over year, even though deposits dropped by 3%. The stock traded up about 1.4% Monday morning.
Charles Schwab beat the consensus earnings per share (EPS) estimate but missed slightly on revenue. Shares traded up about 3.3%.
State Street failed to meet or beat EPS and revenue expectations. Net interest income rose about 50% year over year, but net income overall was down more than 9%. The stock hammered Monday morning, down 12.5%.
Bank of America, BNY Mellon and Goldman Sachs are scheduled to report first-quarter earnings before U.S. markets open on Tuesday, along with Ericsson, Johnson & Johnson and Lockheed Martin. later that day, look for reports from Netflix, United Airlines and Western Alliance Bancorp.
Here is a look at four companies set to report first-quarter results first thing Wednesday morning.
Abbott Labs
Medical device and generic drug maker Abbott Laboratories (NYSE: ABT) has dropped more than 11% from its stock price over the past 12 months. The stock hit a 52-week low in late October and has bounced to a 10% gain since.
Abbott stock was up about 20% from its low in late January before the company revealed that the U.S. Federal Trade Commission had filed a civil investigative demand for information related to issues with the company’s baby formula. The company also faces a criminal investigation by the Department of Justice and numerous civil lawsuits related to its infant formula.
Among 24 analysts covering the stock, 18 have a Buy or Strong Buy rating and five more rate it at Hold. The median price target is $118.00, and with shares currently around $104.70, the upside potential is 12.7%. At the high target of $136.00, the upside potential increases to 29.9%.
First-quarter revenue is forecast to drop sequentially by about 4.4% to $9.64 billion and to decrease by 23.3% year over year. Adjusted EPS are forecast at $0.98, down by 4.6% sequentially and by 43.3% year over year. For the full 2023 fiscal year, analysts are looking for adjusted EPS of $4.39, down 17.8%, on revenue of $39.86 billion, down 8.7%.
Abbott Labs stock trades at 23.8 times expected 2023 EPS, 21.9 times estimated 2024 earnings of $4.77 and 19.0 times estimated 2025 earnings of $5.51 per share. The stock’s 52-week trading range is $93.25 to $124.35, and the company pays an annual dividend of $2.04 (yield of 1.96%). Total shareholder return for the past 12 months was negative 9.49%.
Sponsored: Tips for Investing
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
